Cannabidiol (CBD) reduced inflammatory signaling and intracellular triglyceride accumulation in human macrophage-like cells exposed to excess saturated fat, according to a study published in Frontiers in Immunology.
Researchers from Tecnológico de Monterrey in Mexico examined whether CBD could modify the inflammatory and metabolic stress caused by palmitic acid, a common saturated fatty acid associated with obesity and cardiometabolic disease.
The researchers exposed laboratory-grown human macrophage-like cells to palmitic acid for 24 hours. The treatment produced a lipotoxic but viable cell state marked by increased triglyceride storage and changes in the secretion of several inflammatory cytokines.
Palmitic acid significantly increased interleukin-1 beta (IL-1β), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and other inflammatory or immune-regulating molecules. Tumor necrosis factor alpha (TNF-α) also contributed to the broader inflammatory profile, although its increase did not reach statistical significance when analyzed individually.
Co-treatment with CBD reduced several of these responses in a concentration-dependent and cytokine-specific manner. At higher concentrations, CBD reduced IL-1β by approximately 70%, IL-6 by roughly 45% to 65% and MCP-1 by about 80% to 85% compared with cells exposed to palmitic acid alone.
CBD also significantly reduced intracellular triglyceride accumulation. At the highest concentration tested, triglyceride levels were not significantly different from untreated control cells, suggesting CBD nearly prevented the lipid buildup caused by palmitic acid under the experimental conditions.
The treatment did not significantly reduce cell viability.
Researchers separately tested CBD in cells stimulated with lipopolysaccharide, a bacterial component commonly used to produce an acute inflammatory response. CBD also reduced several cytokines in that model, although the pattern differed from the response to palmitic acid.
The authors said the findings suggest CBD acts as a context-dependent regulator of inflammation rather than broadly suppressing immune activity.
“By reducing selected cytokines and intracellular triglyceride accumulation under conditions of lipid excess, CBD emerges as a candidate molecule for further investigation in models of metabolic inflammation,” researchers concluded.
The study was conducted exclusively in laboratory-grown U937-derived macrophage-like cells. Researchers said the results will need to be validated using primary human macrophages and animal models before their potential therapeutic relevance can be determined.
Sponsors:
